Immune response modifier conjugates

1. An IRM conjugate comprising:

a first linker having a first functional group covalently attached to an IRM compound having immunomodulatory activity, at a site on the IRM compound selected to preserve at least a portion of the immunomodulatory activity of the IRM compound, thereby forming an IRM moiety; and

a second moiety having biological activity and a second functional group that is bound to the IRM moiety by way of a covalent bond between the first functional group and the second functional group;

wherein IRM conjugate possesses IRM activity and the biological activity of the second moiety;

and wherein the covalent bond that is a reaction product of the first functional group and the second functional group comprises a disulfide linkage, a thioether linkage, a hydrazone linkage, an oxime linkage, a urea linkage, a thiourea linkage, a hydrazine linkage, a hydroxyl amine linkage, or a nitrone linkage.

2. The conjugate of claim 1 wherein the IRM moiety is an agonist of TLR7 or TLR8.

3. The conjugate of claim 1 wherein the IRM moiety is, or is derived from, an imidazoquinoline amine, a substituted imidazoquinoline amine, a tetrahydroimidazoquinoline amine, a 1,2-bridged imidazoquinoline amine, an imidazopyridine amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, a pyrazolopyridine amine, a pyrazoloquinoline amine, a tetrahydropyrazoloquinoline amine, a pyrazolonaphthyridine amine, or a tetrahydropyrazolonaphthyridine amine.

4. The conjugate of claim 1 wherein the second moiety comprises an antigen.

5. The conjugate of claim 1 wherein the second moiety comprises a targeting moiety.

6. The conjugate of claim 5 wherein the targeting moiety comprises an antibody directed against an antigenic portion of a tumor, target cell, target tissue, or target organ.

7. The conjugate of claim 5 wherein the targeting moiety comprises a non-proteinaceous moiety providing target-specific affinity to a target.

8. The conjugate of claim 1 wherein the IRM moiety is selected from the group consisting of: N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}-6-[(3-mercaptopropanoyl)amino]hexanamide; N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}-6-{[3-(pyridine-2-yldithio)propanoyl]amino}hexanamide; N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-3-mercaptopropanamide; N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-3-(pyridin-2-yldithio)propanamide; N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}-4-hydrazino-4-oxobutanamide; N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}-6-{[3-(2,5-di-oxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl]amino}hexanamide; 1-(4-{4-[4-amino-2-propyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]piperidin-1-yl}-4-oxobutyl)-1H-pyrrole-2,5-dione; N-{3-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)amino]propyl}-3-mercaptopropanamide; N-(2-{2-[2-(2-{[4-amino-2-(ethoxymethyl)-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-7-yl]oxy}ethoxy)ethoxy]ethoxy}ethyl)-3-mercaptopropanamide; N-{6-[(4-amino-2-(ethoxymethyl)-1-{2-methyl-2-[(methylsulfonyl)amino]propyl}-1H-imidazo[4,5-c]quinolin-7-yl)oxy]hexyl}-3-mercaptopropanamide; N-[(4-amino-1-benzyl-1H-imidazo[4,5-c]quinolin-2-yl)methyl]-3-mercaptopropanamide; and N-(2-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]oxy}ethyl)-3-mercaptopropanamide; or a pharmaceutically acceptable salt thereof.

9. The IRM conjugate of claim 1 , wherein the covalent bond that is the reaction product of the functional group with the second functional group comprises a disulfide linkage or a thioether linkage, and wherein the first functional group comprises a thiol.

10. The IRM conjugate of claim 1 , wherein the covalent bond that is the reaction product of the first functional group with the second functional group comprises a hydrazone linkage or a hydrazine linkage, and wherein the first functional group is a 1-4-dioxo-4-hydrazino-butyl.